Elevance Health closed at a fresh one-year high of $446.42, 0.26% above its prior peak set on October 22. Competitor Clover Health slipped 0.2% on the day.
- Dec 31, 2025 · SEC 10-K
Moves: Nov 16, 2026 · Alpha Vantage daily close
2 have no US listing
Headquartered in Indianapolis, IN Fiscal year ends December NYSE: ELV elevancehealth.com
Elevance Health, Inc. (NYSE: ELV) is a diversified health services company that serves approximately 104 million consumers through a portfolio of medical, pharmacy, behavioral, clinical, home health, and complex care solutions. The company operates through four reportable segments: Health Benefits (encompassing Individual/ACA, Employer Group risk-based and fee-based, BlueCard, Medicare, Medicaid, and Federal Employee Program businesses), CarelonRx (pharmacy services including specialty pharmacy), Carelon Services (healthcare services and risk-based care solutions), and Corporate & Other. As of June 30, 2026, Elevance Health had approximately 44.9 million medical members. The company is a Blue Cross Blue Shield licensee and is focused on medical cost management, member experience, provider connectivity, operating efficiency, and value-based care through its Carelon platform. Updated
Elevance Health closed at a fresh one-year high of $446.42, 0.26% above its prior peak set on October 22. Competitor Clover Health slipped 0.2% on the day.
Moves: Nov 16, 2026 · Alpha Vantage daily close
2 have no US listing
Sellers controlled the close, with iQIYI down 17.27% on the day it filed third quarter results and no gainer topping a fraction of that. Healthcare took the top three slots after Bill Holdings.
Healthcare is leading at the open while AI hardware lags: SanDisk, Coherent, Lumentum and ASE Technology are all down roughly 8.5% or more, with Elevance, HCA and Gilead on the upside. iQIYI drops 14.7% after filing its third-quarter earnings report this morning.
The 9.05% run came the same day Humana, a competitor, posted Q3 2026 results. Managed care names moved together into the close.
Humana Q3 2026 earnings release
Moves: Nov 6, 4:20 PM ET · Alpha Vantage quote
3 more related stocks · 4 have no US listing
Elevance's CFO cut roughly a third of his reported common stock in one day, selling 10,584 shares for about $4.65 million into prices as high as $447.19. No 10b5-1 plan is flagged, which makes this a discretionary exit by the person who knows the Medicare Advantage cost math best.
The managed-care insurer heads into today's earnings report already on the back foot, down 4.38% on the day. That slide sets a low bar for how the report lands.
Elevance reports before the open at 6:00 AM ET with four straight EPS beats behind it, the last one topping estimates by 20.6%. Consensus sits at $4.69 on $49.16 billion in revenue, and Medicare Advantage cost trends are the line that decides how insurers trade today.
Elevance Health just set a new 52-week high at $425.27, a full round trip from its March low.
Wall Street is punishing CVS Health (NYSE:CVS | CVS Price Prediction) for a plan to break up the pharmacy, benefits and insurance empire it spent years building, even after a strong quarter.…
Senator Elizabeth Warren opened November by targeting UnitedHealth Group (NYSE:UNH | UNH Price Prediction) again. In a Sunday post on X, she went after the company’s purchase of Amedisys: “Now Trump’s DOJ…
UnitedHealth has shed members, slipped 10% in three months, and closed lower on a beat-and-raise quarter. Now a major Wall Street firm is calling for 40% gains, and its argument centers on…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) shares are up 4% to $395.19 after the health insurer topped Q3 2026 profit estimates and raised its full-year outlook. The beat came on the…
UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time. Whether that something is enough to make UNH worth holding…
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped…
Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a…
Seth Klarman's Baupost Group just revealed its five largest stock positions, and the list includes a little-known industrial distributor posting explosive earnings growth alongside household names bleeding on the front page. Reverse-engineering…
RSP is beating SPY for the first time in years, but two specific signals will determine whether equal-weight strategies keep their edge or surrender it back to the mega-caps before year end.
Your Medicare Advantage plan stays active on paper, but the hospital you have used for decades can quietly vanish from your network before your next appointment, and the protections meant to help…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) carries the highest conviction among managed care names heading into the company’s July 16 earnings report, and the setup is doing the talking. Shares of…
Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution. They negotiate rebates, design formularies, adjudicate claims, and steer patient adherence. Modern artificial intelligence (AI) is designed to compress each…
Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by Gabelli Funds that has quietly paid quarterly distributions for more than 14…
Elevance Health (NYSE:ELV | ELV Price Prediction) stock surged this week after the Centers for Medicare & Medicaid Services finalized a 2.48% Medicare Advantage payment rate increase for 2027, coming in above…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is up nearly 11% today, moving from $281.36 to $311 and change, as the managed care sector stages a powerful relief rally. Humana (NYSE:HUM)…
Elevance Health, Inc. (NYSE: ELV) is a diversified health services company that serves approximately 104 million consumers through a portfolio of medical, pharmacy, behavioral, clinical, home health, and complex care solutions.
24/7 Wall St.'s 12-month price target for ELV is $654.78, rated Buy. The Wall Street consensus target is $482.38. ELV price prediction →